Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

JAMA

Volumn 288, Issue 1, 2002, Pages 58-66

  Hulley, Stephen ^a   Furberg, Curt ^b   Barrett Connor, Elizabeth ^c   Cauley, Jane ^d   Grady, Deborah ^a   Haskell, William ^e   Knopp, Robert ^f   Lowery, Maureen ^g   Satterfield, Suzanne ^h   Schrott, Helmut ⁱ   Vittinghoff, Eric ^a   Hunninghake, Donald ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE;

AGED; ARTICLE; BILIARY TRACT SURGERY; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM;

EID: 0037014630     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.1.58     Document Type: Article

References (43)

1. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
2. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/progestin Replacement Study
3. Risk of venous thromboembolism in users of hormone replacement therapy
4. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
5. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease
6. Heart and Estrogen/progestin Replacement Study (HERS): Design, methods, and baseline characteristics
7. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
8. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
9. Prospective study of exogenous hormones and risk of pulmonary embolism in women
10. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
11. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
12. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
13. Oral contraceptives and the risk of venous thrombosis
14. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women
15. Venous thromboembolic events associated with hormone replacement therapy
16. Gallbladder disease as a side effect of drugs influencing lipid metabolism: Experience in the Coronary Drug Project
17. Pathogenesis and treatment of gallstones
18. Findings leading to discontinuation of the 2.5 mg/day estrogen group
19. Estrogen and the risk of breast cancer
20. Hormone replacement therapy increases the risk of breast cancer
21. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
22. Women and lung cancer: Does oestrogen play a role?
23. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis
24. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
25. Current perspectives on oral contraceptive use
26. Hormone therapy to prevent disease and prolong life in postmenopausal women
27. Estrogen replacement therapy and fractures in older women: Study of Osteoporotic Fractures
28. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
29. Bone mineral density response to estrogen replacement in frail elderly women: A randomized controlled trial
30. Does hormone replacement therapy prevent nonvertebral fractures: A review of randomized trials and meta-analysis
31. Postmenopausal hormone therapy for prevention of fractures: How good is the evidence?
32. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/progestin Replacement Study (HERS)
33. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
34. Effect of risedronate on the risk of hip fracture in elderly women: HIP Intervention Program
35. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
36. Postmenopausal hormone therapy and mortality
37. Postmenopausal estrogen and prevention bias
38. Coronary heart disease and estrogen replacement therapy: Can compliance bias explain the results of observational studies?
39. Prior to use of estgrogen replacement therapy, are users healthier than nonusers?
40. Hormones to prevent coronary disease in women: When are observational studies adequate evidence?
41. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions Trial
42. Oral estrogen replacement therapy versus placebo for hot flushes: A systematic review
43. Design of the Women's Health Initiative clinical trial and observational study